v3.25.3
Revenue
 9 Months Ended
Oct. 03, 2025
Revenue [Abstract]  
Revenue Revenue
The Company provides orthopedic solutions, including products and services spanning the full continuum of patient care, from injury prevention to rehabilitation. While the Company’s sales are primarily derived from three sales channels including dealers and distributors, insurance, and direct to consumers and hospitals, substantially all of the Company’s revenue is recognized at a point in time. The Company disaggregates its revenue into the following geographic/product type groups within its segments:

Three Months EndedNine Months Ended
October 3, 2025September 27, 2024October 3, 2025September 27, 2024
(In thousands)
Prevention & Recovery:
U.S. Bracing & Support$126,980 $123,021 $362,916 $345,132 
U.S. Other P&R71,408 66,196 208,853 200,496 
International P&R92,551 85,027 282,324 265,383 
Total Prevention & Recovery290,939 274,244 854,093 811,011 
Reconstructive:
U.S. Recon128,979 120,811 396,349 366,608 
International Recon128,994 110,167 421,849 369,029 
Total Reconstructive 257,973 230,978 818,198 735,637 
Total$548,912 $505,222 $1,672,291 $1,546,648 

Given the nature of its businesses, the Company does not generally have unsatisfied performance obligations with an original contract duration of greater than one year.

The nature of the Company’s contracts gives rise to certain types of variable consideration, including rebates, implicit price concessions, and other discounts. The Company includes estimated amounts of variable consideration in the transaction price to the extent that it is probable there will not be a significant reversal of revenue.

Allowance for Credit Losses

The Company’s estimate of current expected credit losses on trade receivables considers historical credit loss information that is adjusted for current conditions and reasonable and supportable forecasts. In calculating and applying its current expected credit losses, the Company disaggregates trade receivables into business segments due to risk characteristics unique to each segment given the individual lines of business and market. The business segments are further disaggregated based on either geography or product type. The Company uses a loss rate methodology in calculating its current expected credit losses, considering historical write-offs over a defined lookback period in deriving a historical loss rate. The expected credit loss model considers current conditions and reasonable and supportable forecasts for current and projected macroeconomic factors.

A summary of the activity in the Company’s allowance for credit losses included within Trade receivables in the Condensed Consolidated Balance Sheets is as follows:
Nine Months Ended October 3, 2025
Balance at
Beginning
of Period		Charged to Expense, netWrite-Offs, Deductions, and Other, netForeign
Currency
Translation		Balance at
End of
Period
(In thousands)
Allowance for Credit Losses$24,466 $1,864 $(969)$1,277 $26,638